Skip to main content

Table 4 Results of this analysis

From: Efficacy and safety of adding rivaroxaban to the anti-platelet regimen in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials

Outcomes which were assessed OR with 95% CI P value I2 (%)
Composite endpoint 0.81 [0.74–0.88] 0.00001 19
All-cause mortality 0.82 [0.72–0.92] 0.0009 0
Cardiac death 0.80 [0.69–0.92] 0.002 0
Myocardial infarction 0.87 [0.77–0.98] 0.03 10
Stent thrombosis 0.73 [0.55–0.97] 0.03 28
Stroke 0.77 [0.43–1.38] 0.38 81
TIMI defined minor bleeding 2.27 [1.47–3.49] 0.0002 0
TIMI defined major bleeding 3.44 [1.13–10.52] 0.03 74
Intracranial bleeding 1.63 [1.04–2.56] 0.03 44
Fatal bleeding 1.19 [0.74–1.91] 0.48 0
ISTH bleeding 1.80 [1.45–2.22] 0.00001 0
  1. TIMI thrombolysis in myocardial infarction, ISTH International Society on Thrombosis and Hemostasis, OR odds ratios, CI confidence intervals